Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product ...
Abstract Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an in vitro antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs.…
related reading
- How to make an antibody - Works in Progress Magazineworksinprogress.co
- In vitro-engineered non-antibody protein therapeuticsncbi.nlm.nih.gov
- A primer on machine learning in antibody engineeringabhishaike.com
- Mesa — JURA Bio, Inc.jura.bio
- Boosting therapeutic potency of antibodies by taming Fc domain functions | Experimental & Molecular Medicinenature.com
- Current progress in innovative engineered antibodies | Protein & Cell | Springer Nature Linklink.springer.com
- Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
- Antibody Structure - BioAtlabioatla.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- One-shot design of functional protein binders with BindCraftnature.com
- Bacteriophage - Wikipediaen.wikipedia.org
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev